Crispr Therapeutics AG (CRSP)

[janetcanada]

CRSP - From: Simply Wall St™

***Revenue is forecast to grow 49.88% per year

*Pass
Are revenue and earnings forecast to grow?

Earnings are forecast to grow by an average of 52.4% per year for the next 3 years
Section 2.1

*Pass
Are they in a good financial position?

They have sufficient cash for at least 1 year of operations
Section 4.4

Pass
Is their dividend sustainable?

They do not pay a dividend
Section 5.0

*Pass
Is their share price liquid and stable?

Share price has been stable over the past 3 months

Pass
Do they have sufficient financial data available?

They have sufficient analyst coverage
Section 2.0

Pass
Are there any concerning recent events?

No concerning events detected

Pass
Do they have a meaningful market capitalization?

Market cap is meaningful ($4B)
Section 8.0

*Pass
Do they have negative shareholders equity?

CRSP does not have negative shareholders

***CRISPR Therapeutics NasdaqGM:CRSP Stock Report

***Simply Wall St
https://simplywall.st › ... › Pharmaceuticals & Biotech
====================================================

***Founded Employees CEO Website
2013 458 Sam Kulkarni https://www.crisprtx.com
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics.

CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.